RE: MAtins RNS1 Jun 2020 08:12
Good to see that Covid isn't slowing progress .
Recruitment going well
Matins investigator seems very happy with Faron - even 'excited'
Dr. Petri Bono, the Principle Investigator of the MATINS study, said:
The MATINS trial's Part I results have shown a tolerable safety profile for Clevegen, as well as exciting clinical activity in the target lesions of several terminal cancer patients. Clevegen represents a novel mechanism of action and this macrophage checkpoint inhibition has already, in Part I of the trial, shown clinical response in immunologically 'cold' tumours traditionally not responsive to currently available checkpoint inhibitors. I very much look forward to continuing patient enrolment for Part II of the trial, which is progressing well for the selected tumour types."